Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report

Abstract Background Immune checkpoint inhibitors are new immunotherapy drugs globally used for many malignancies, including renal cell carcinoma. Myocarditis as an immune-related adverse event is rare but highly fatal, suggesting that its frequency may be higher than reported. This paper describes a...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Yasuyuki Miyauchi, Hirohito Naito, Hiroyuki Tsunemori, Ryosuke Tani, Yusuke Hasui, Yuichi Miyake, Tetsuo Minamino, Ryo Ishikawa, Yoshio Kushida, Reiji Haba, Mikio Sugimoto
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2021-10-01
Ráidu:	Journal of Medical Case Reports
Fáttát:	Immunotherapy Immune checkpoint inhibitors Nivolumab Ipilimumab Immune-related adverse events Myocarditis
Liŋkkat:	https://doi.org/10.1186/s13256-021-03097-6
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!